Holen Sie sich die Stockscreener-App
13.03
1.67%
-0.2142
Schlusskurs vom Vortag:
$13.24
Offen:
$13.22
24-Stunden-Volumen:
589.49K
Relative Volume:
0.25
Marktkapitalisierung:
$4.10B
Einnahmen:
$3.02B
Nettoeinkommen (Verlust:
$127.93M
KGV:
58.86
EPS:
0.2213
Netto-Cashflow:
$225.64M
1W Leistung:
-5.46%
1M Leistung:
-10.34%
6M Leistung:
+31.63%
1J Leistung:
+46.28%
1-Tages-Spanne:
$12.84
$13.29
1-Wochen-Bereich:
$12.84
$13.47
52-Wochen-Spanne:
$6.685
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.03 | 4.17B | 3.02B | 127.93M | 225.64M | 0.2213 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.95 | 56.49B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
119.78 | 51.26B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.79B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.77 | 36.16B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
515.51 | 20.96B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Trade Report: Will Amneal Pharmaceuticals Inc benefit from current market trends2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Resistance Check: Does Amneal Pharmaceuticals Inc stock have upside surprise potentialWeekly Investment Recap & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal to Participate in Upcoming Investor Conference - National Today
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants - Stock Titan
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan
AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat
Truist raises Amneal Pharmaceuticals stock price target on margin focus By Investing.com - Investing.com Canada
Truist raises Amneal Pharmaceuticals stock price target on margin focus - Investing.com
Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating - marketscreener.com
Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - Sahm
Earnings Miss: Can Amneal Pharmaceuticals Inc be the next market leaderQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Envestnet Asset Management Inc. Takes $1.61 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative - Sahm
Earnings call transcript: Amneal Pharmaceuticals beats expectations in Q4 2025 - Investing.com Australia
Why Amneal (AMRX) Stock Is Trading Lower Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) grows biosimilars, Parkinson’s and injectables - Stock Titan
Amneal (AMRX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Amneal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Amneal Q4 2025 slides: specialty surge drives 11% revenue growth - Investing.com
Amneal Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-02-27 - Seeking Alpha
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million - Benzinga
Amneal Posts Strong Q4 Results and Raises 2026 Outlook - TipRanks
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations - Finviz
Amneal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals : Fourth Quarter 2025 Earnings Presentation - marketscreener.com
Amneal Pharmaceuticals beats Q4 estimates, guides below views - Investing.com
AMNEAL PHARMACEUTICALS ($AMRX) Releases Q4 2025 Earnings - Quiver Quantitative
Amneal (NASDAQ: AMRX) returns to profit and guides 2026 growth - Stock Titan
(AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B to $3.15B, vs. FactSet Est of $3.21B - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q4 Revenue $814.3M, vs. FactSet Est of $807.4M - marketscreener.com
(AMRX) Amneal Pharmaceuticals Expects 2026 Adjusted EPS Range $0.93 to $1.03, vs. FactSet Est of $0.94 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.18 - marketscreener.com
Amneal Pharmaceuticals Reports Strong Full Year 2025 Financial Results and Confident 2026 Guidance - Quiver Quantitative
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.87%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):